Cumberland Pharmaceuticals Inc., a U.S. specialty pharmaceutical company and Clinigen Group, the global pharmaceutical and services company, announce a new publication in Lung Cancer: Targets and Therapy of a contemporary retrospective series showing that subcutaneous amifostine administered before radiotherapy postponed the onset of acute esophagitis in stage III small cell lung cancer patients treated with concomitant doublet chemotherapy and hyperfractionated radiotherapy.
“Your entire practice, cancer has been associated with an aging population, and then you have a young, beautiful, healthy-looking woman like Alisa Secaida come into your office, it's not a surprise that the doctor, their knee-jerk reaction would be like, ‘Maybe just slow down,’” said The Cancer Letter’s Claire Marie Porter.
